Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
BETAMETHASONDIPROPIONAAT 0,64 mg/g SAMENSTELLING overeenkomend met ; BETAMETHASON 0,5 mg/g ; CALCIPOTRIOL 1-WATER 52,2 µg/g SAMENSTELLING overeenkomend met ; CALCIPOTRIOL 50 µg/g
Sandoz B.V. Veluwezoom 22 1327 AH ALMERE
D05AX52
BETAMETHASONDIPROPIONAAT 0,64 mg/g SAMENSTELLING overeenkomend met ; BETAMETHASON 0,5 mg/g ; CALCIPOTRIOL 1-WATER 52,2 µg/g SAMENSTELLING overeenkomend met ; CALCIPOTRIOL 50 µg/g
Zalf
OLEYLALCOHOL ; PARAFFINE, DUNVLOEIBAAR ; PARAFFINE, ZACHT (E 905) ; TOCOFEROL, DL-ALFA (E 307),
Cutaan gebruik
Calcipotriol, Combinations
Hulpstoffen: OLEYLALCOHOL; PARAFFINE, DUNVLOEIBAAR; PARAFFINE, ZACHT (E 905); TOCOFEROL, DL-ALFA (E 307);
1900-01-01
Sandoz B.V. Page 1/7 Calcipotriol/Betamethason Sandoz 50 microgram/g +0,5 mg/g, zalf RVG 117920 1313-v5 1.3.1.3 Bijsluiter November 2019 PACKAGE LEAFLET: INFORMATION FOR THE USER CALCIPOTRIOL/BETAMETHASON SANDOZ 50 MICROGRAM/G + 0,5 MG/G, ZALF calcipotriol/betamethasone READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What [Nationally completed name] is and what it is used for 2. What you need to know before you take [Nationally completed name] 3. How to use [Nationally completed name] 4. Possible side effects 5. How to store [Nationally completed name] 6. Contents of the pack and other information 1. WHAT [NATIONALLY COMPLETED NAME] IS AND WHAT IS USED FOR [Nationally completed name] ointment is used on the skin to treat plaque psoriasis (psoriasis vulgaris) in adults. Psoriasis is caused by your skin cells being produced too quickly. This causes redness, scaling and thickness of your skin. [Nationally completed name] ointment contains calcipotriol and betamethasone. Calcipotriol helps to bring the rate of skin cell growth back to normal and betamethasone acts to reduce inflammation. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE [NATIONALLY COMPLETED NAME] DO NOT USE [Nationally completed name] • If you are allergic to calcipotriol, betamethasone or any of the other ingredients of this medicine (listed in section 6) • If you have problems with calcium levels in the body (ask your doctor) • If you have certain types of psoriasis: these are erythrodermic, exfoliative and pustular (ask your doctor). As Lees het volledige document
Sandoz B.V. Page 1/11 Calcipotriol/Betamethason Sandoz 50 microgram/g + 0,5 mg/g, zalf RVG 117920 1311-V6 1.3.1.1 Samenvatting van de Productkenmerken Mei 2023 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Calcipotriol/Betamethason Sandoz 50 microgram/g + 0,5 mg/g, zalf 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of ointment contains 50 micrograms of calcipotriol (as monohydrate) and 0.5 mg of betamethasone (as dipropionate). For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Ointment. Off white. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Topical treatment of stable plaque psoriasis vulgaris amenable to topical therapy in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology [Nationally completed name] ointment should be applied to the affected area once daily. The recommended treatment period is 4 weeks. There is experience with repeated courses of [Nationally completed name] up to 52 weeks. If it is necessary to continue or restart treatment after 4 weeks, treatment should be continued after medical review and under regular medical supervision. When using calcipotriol containing medicinal products, the maximum daily dose should not exceed 15 g. The body surface area treated with calcipotriol containing medicinal products should not exceed 30 % (see section 4.4). Special populations Sandoz B.V. Page 2/11 Calcipotriol/Betamethason Sandoz 50 microgram/g + 0,5 mg/g, zalf RVG 117920 1311-V6 1.3.1.1 Samenvatting van de Productkenmerken Mei 2023 _Renal and hepatic impairment _ The safety and efficacy of [Nationally completed name] ointment in patients with severe renal insufficiency or severe hepatic disorders have not been evaluated. _Paediatric population _ The safety and efficacy of [Nationally completed name] ointment in children below 18 years have not been established. Currently available data in children aged 12 to 17 years are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made. _ _ _Method of administration _ Lees het volledige document